As head of Clinical Development, Late Oncology I am accountable for the development and resourcing for the physicians and scientists who are currently responsible for studies in late oncology from Phase I signal seeking to Ph3 registrational trials spanning multiple Oncology indications.
Additionally as a Clinical Strategy Head, I lead the company’s global research and development in lung cancer, a disease that despite many gains in recent years, remains the most common cause of cancer related mortality around the world. In my role, I partner with teams from across AstraZeneca Oncology to rapidly progress our research and deliver on our commitment to eliminate cancer as a cause of death.
Prior to joining AstraZeneca I earned a medical degree from University of Toronto, where I trained in internal medicine and medical oncology, and also received a Masters of Science in Pharmacology. I completed a Thoracic Fellowship at Vanderbilt University where I went on to lead the lung cancer program for over a decade. Following my passion for people development, I completed a Masters in Health Professions Education from the University of Illinois, and developed faculty development programs for clinician educators and researchers.
I have served as principal investigator on several national and global lung cancer trials for immunotherapies, targeted therapies and novel treatments across early and late development, and have published more than 175 papers and book chapters. I am also an active member and served on the scientific committees of the American Society of Clinical Oncology, the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.
It is energizing to be part of AstraZeneca, working with brilliant teams at an inspiring pace, driven by a shared purpose, to bring new therapies to patients and eliminate cancer as a cause of death. We focus on learning, development and delivery of high-quality innovative studies to redefine cancer care. I’m excited about the work we’re doing to improve screening, identify novel populations and biomarkers as we deliver the next wave of treatments for patients with lung cancer.
CURRENT ROLE
2009-2020
2009-2015
2008-2009